05-538
Anti-phospho-Raf-1 (Ser338) Antibody
Upstate®, from mouse
Synonyme(s) :
Anti-CMD1NN, Anti-CRAF, Anti-NS5, Anti-Raf-1, Anti-c-Raf
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Sélectionner une taille de conditionnement
200 μG
526,00 €
Sélectionner une taille de conditionnement
Changer de vue
200 μG
526,00 €
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
monoclonal
Espèces réactives
mouse
Fabricant/nom de marque
Upstate®
Technique(s)
western blot: suitable
Isotype
IgG
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Modification post-traductionnelle de la cible
phosphorylation (pSer338)
Informations sur le gène
human ... RAF1(5894)
Spécificité
Recognizes Raf-1 phosphorylated at Serine 338.
Immunogène
Peptide corresponding to residues 333-345 of human Raf-1
Application
Anti-phospho-Raf-1 (Ser338) Antibody detects level of phospho-Raf-1 (Ser338) & has been published & validated for use in WB.
Research Category
Signaling
Signaling
Research Sub Category
MAP Kinases
MAP Kinases
Qualité
routinely evaluated by immunoblot on RIPA lysates from 3T3/NIH cells stimulated with PDGF
Description de la cible
74 kDa
Forme physique
Format: Purified
Protein A Purified immunoglobulin in Protein A Purified immunoglobulin in 0.1M Tris-Glycine, 0.15M NaCl, 0.05% sodium azide, pH 7.4.
Protein G Purified
Stockage et stabilité
Stable for 1 year at 2-8°C from date of receipt.
Remarque sur l'analyse
Control
Expressed in most tissue, lysates from 3T3/NIH cells stimulated with PDGF
Expressed in most tissue, lysates from 3T3/NIH cells stimulated with PDGF
Autres remarques
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informations légales
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 1
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Antonia K Roseweir et al.
Journal of the National Cancer Institute, 110(6), 616-627 (2018-06-20)
Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show
Development of a highly reproducible three-dimensional organotypic model of the oral mucosa.
Anna Dongari-Bagtzoglou, Helena Kashleva
Nature Protocols null
Culture of Drosophila primary cells dissociated from gastrula embryos and their use in RNAi screening.
Bai J, Sepp KJ, Perrimon N
Nature Protocols null
Yijun Gao et al.
Cancer discovery, 8(5), 648-661 (2018-02-28)
Mutations at multiple sites in MEK1 occur in cancer, suggesting that their mechanisms of activation might be different. We analyzed 17 tumor-associated MEK1 mutants and found that they drove ERK signaling autonomously or in a RAS/RAF-dependent manner. The latter are
Yulei Zhao et al.
Nature, 599(7886), 679-683 (2021-11-12)
Inactive state-selective KRAS(G12C) inhibitors1-8 demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class mutant GTPase inhibitors remains under investigation. Here we evaluated matched pre-treatment
Filtres actifs
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique
